<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02639182</url>
  </required_header>
  <id_info>
    <org_study_id>AGS-16C3F-15-3</org_study_id>
    <nct_id>NCT02639182</nct_id>
  </id_info>
  <brief_title>A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma</brief_title>
  <official_title>A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the progression free survival (PFS), based on
      investigator radiologic review, of AGS-16C3F compared to axitinib in subjects with metastatic
      renal cell carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 24, 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as the time from the date of randomization to the earliest of documented disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS calculated based on blinded central radiology assessment per RECIST v.1.1</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) based on the investigator's radiographic assessment</measure>
    <time_frame>24 months</time_frame>
    <description>ORR is defined as the proportion of subjects who have a best overall response of Complete Response (CR) or Partial Response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) based on the investigator's radiographic assessment</measure>
    <time_frame>24 months</time_frame>
    <description>DOR is defined as the time from the date of the first response of CR/PR (whichever is first recorded) to the first date of documented progressive disease or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>OS is defined as the number of months from the date of randomization until the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) assessed by the investigator's radiographic assessment</measure>
    <time_frame>24 months</time_frame>
    <description>DCR is defined as the proportion of subjets who have a best overall response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) with a minimum duration of 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile assessed by Incidence of adverse events (AEs), laboratory tests, vital signs and electrocardiograms (ECG)</measure>
    <time_frame>24 months</time_frame>
    <description>Laboratory tests include hematology and chemistry. Vital signs include blood pressure, heart rate, and respiratory rate.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>AGS-16C3F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AGS-16C3F will be administered as a single 60-minute intravenous (IV) infusion once every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Axitinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Axitinib will be administered twice daily continuously, by mouth.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGS-16C3F</intervention_name>
    <description>Intravenous (IV) infusion</description>
    <arm_group_label>AGS-16C3F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Axitinib</intervention_name>
    <description>Oral</description>
    <arm_group_label>Axitinib</arm_group_label>
    <other_name>Inlyta®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of RCC

               -  Non-clear subjects must be ENPP3 positive, defined as IHC H-score ≥15

          -  Has evidence of progression on or after the last regimen received:

               -  Clear cell subject: must have received at least 2 prior systemic regimens, one of
                  which is an anti-VEGF agent.

               -  Non-clear cell subject: must have received at least one prior anti-VEGF regimen

          -  Has measurable disease according to Response Criteria for Solid Tumors (RECIST v.1.1)

          -  Has Eastern Cooperative Group (ECOG) performance status of 0 or 1

          -  Has archive tumor tissue from primary tumor or metastatic site (excluding bone), for
             which the source and availability have been confirmed.

               -  If no archive tissue is available, the subject may elect to have a biopsy
                  performed to obtain tissue.

          -  Has adequate organ function including:

               -  Hematopoietic function as follows:

                    1. Absolute neutrophil count (ANC) ≥ 1.5 x 10 9/L

                    2. Platelet count ≥ 100 x 10 9/L

                    3. Hemoglobin ≥ 9 g/dL (transfusions are allowed)

               -  Renal Function as follows:

                  1. Creatinine ≤ 1.5 x upper limit of normal (ULN), or calculated glomerular
                  filtration rate (GFR) &gt; 40 mL/min (Cockcroft-Gault) if creatinine &gt; 1.5x ULN

               -  Hepatic function, as follows:

                    1. Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2.5 x
                       ULN or ≤ 5x ULN if known liver metastases

                    2. Total bilirubin ≤ 1.5 x ULN

          -  Prothrombin time (PT) and activated partial thromboplastin time (aPTT) levels ≤1.5 x
             ULN. If institution does not report PT value, the international normalization ratio
             (INR) must be ≤ ULN.

               -  If subject is receiving Coumadin (warfarin), a stable international normalization
                  ratio (INR) of 2-3 is required.

          -  No clinical symptoms of hypothyroidism

          -  Urine Protein to Creatinine Ratio (uPCR) &lt; 2.0

               -  If uPCR ≥ 2.0 then a 24-hour urine collection can be performed to qualify. If
                  this is performed to qualify, the protein result must be &lt; 2 g per 24 hours.

          -  Female subject must either:

               -  Be of non-childbearing potential:

                    1. post-menopausal (defined as at least 1 year without any menses) prior to
                       Screening, or

                    2. documented surgically sterile

               -  Or, if of childbearing potential,

                    1. Agree not to try to become pregnant during the study and for 6 months after
                       the final study drug administration

                    2. And have a negative serum pregnancy test ≤ 10 days of cycle 1, day 1 (C1D1)

               -  And, if heterosexually active, agree to consistently use 2 forms of highly
                  effective birth control* (at least one of which must be a barrier method)
                  starting at Screening and throughout the study period and for 6 months after the
                  final study drug administration.

          -  Female subject must agree not to breastfeed starting at Screening and throughout the
             study period, and for 6 months after the final study drug administration.

          -  Female subject must not donate ova starting at Screening and throughout the study
             period, and for 6 months after the final study drug administration.

          -  Male subject and their female spouse/partners who are of childbearing potential must
             be using highly effective contraception* consisting of 2 forms of birth control (at
             least one of which must be a barrier method) starting at Screening and continue
             throughout the study period, and for 6 months after the final study drug
             administration

          -  Male subject must not donate sperm starting at Screening and throughout the study
             period and, for 6 months after the final study drug administration

        Note: *Highly effective forms of birth control include:

          -  Consistent and correct usage of established oral contraception.

          -  Established intrauterine device (IUD) or intrauterine system (IUS).

          -  Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault
             caps) with spermicidal foam/gel/film/cream/suppository

        Exclusion Criteria:

          -  Has previously been treated with axitinib, AGS-16C3F, or AGS-16M8F

          -  Has untreated brain metastasis. In the case of a solitary brain metastasis which has
             been resected, there must be evidence of a disease-free interval of at least 3 months
             post-surgery. For brain metastases treated with whole brain or stereotactic radiation
             therapy, brain imaging must be stable &gt; 3 months. All subjects previously treated for
             brain metastases must be stable off corticosteroid therapy for at least 28 days prior
             to C1D1.

          -  Has uncontrolled hypertension defined as blood pressure &gt; 150/90 on medication(s) by 2
             blood pressure readings taken at least 1 hour apart.

          -  Has gastrointestinal abnormalities including:

               -  inability to take oral medication;

               -  requirement for intravenous alimentation;

               -  prior surgical procedures affecting absorption including total gastric resection;

               -  active gastrointestinal bleeding, unrelated to cancer, as evidenced by
                  hematemesis, hematochezia or melena in the past 3 months without evidence of
                  resolution documented by endoscopy or colonoscopy;

               -  malabsorption syndromes such as celiac disease, cystic fibrosis, inflammatory
                  bowel disease, systemic sclerosis, and carcinoid syndrome

          -  Has ocular conditions such as:

               -  Active infection or corneal ulcer

               -  Monocularity

               -  Visual acuity of 20/70 or worse in both eyes

               -  History of corneal transplantation

               -  Contact lens dependent (if using contact lens, must be able to switch to glasses
                  during the entire study duration)

               -  Uncontrolled glaucoma (topical medications allowed)

               -  Uncontrolled or active ocular problems (e.g., retinopathy, macular edema, active
                  uveitis, wet macular degeneration) requiring surgery, laser treatment, or
                  intravitreal injections

               -  Papilledema or other active optic nerve disorder

          -  Has used any investigational drug (including marketed drugs not approved for this
             indication) ≤ 14 days of C1D1. No time limit applies to the use of marketed drugs
             approved for this indication provided that the subject has progressed on the treatment
             and all toxicities attributable to the drug have resolved, returned to baseline or
             stabilized.

          -  Has known sensitivity to any of the ingredients of:

               -  investigational product AGS-16C3F and/or,

               -  Inlyta® (axitinib) and/or,

               -  1% prednisolone acetate ophthalmic suspension and any other corticosteroids.

          -  Is currently using (i.e., within 14-days prior to first dose) drugs that are known
             strong CYP3A4/5 inhibitors / inducers.

          -  Thromboembolic event (e.g., deep vein thrombosis [DVT] and pulmonary embolism [PE]) ≤
             4 weeks of C1D1.

               -  Subjects who had a thromboembolic event ≤ 4 weeks of C1D1 must be receiving
                  adequate anticoagulation treatment for at least 2 weeks before C1D1 and must
                  continue as clinically indicated post first dose

          -  Has history bleeding disorders (e.g., pulmonary hemorrhage, significant hemoptysis,
             menometrorrhagia not responding to hormonal treatment) ≤ 2 months before C1D1

          -  Has active angina or Class III or IV Congestive Heart Failure (New York Heart
             Association CHF Functional Classification System) or clinically significant cardiac
             disease within 6 months of randomization, including myocardial infarction, unstable
             angina, Grade 2 or greater peripheral vascular disease, congestive heart failure, or
             arrhythmias not controlled by medication.

          -  Had major surgery ≤ 4 weeks of C1D1

          -  Is pregnant (confirmed by positive serum pregnancy test) or lactating

          -  Has active infection requiring treatment with systemic (intravenous or oral)
             anti-infectives (antibiotic, antifungal, or antiviral agent) ≤ 10 days of C1D1

          -  Is unwilling or unable to comply with study requirements

          -  Has any medical or psychiatric disorder that compromises the ability of the subject to
             give written informed consent, and/or comply with the study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Associate Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Astellas Pharma Global Development, Inc.</last_name>
    <phone>800-888-7704</phone>
    <email>Astellas.registration@astellas.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site US01026</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US01016</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site US01008</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US01007</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US01020</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US01019</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US01010</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US01023</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US01002</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US01004</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US01013</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US01018</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site US01012</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US01005</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site US01006</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US01022</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US01015</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site US01017</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US01021</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US01011</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US01025</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US01003</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US01014</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US01001</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site US01009</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CA02006</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CA02004</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CA02005</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CA02001</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CA02002</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site CA02008</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2015</study_first_submitted>
  <study_first_submitted_qc>December 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2015</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Axitinib</keyword>
  <keyword>Metastatic Renal Cell Carcinoma</keyword>
  <keyword>AGS-16C3F</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Axitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

